Buradasınız

Anasayfa » Content

PHARMACOKINETIC OF RENAL FAILURE THERAPY

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2012

Key Words:

Author NameFaculty of Author
Abstract (2. Language): 
Renal failure (loss of kidney normal functionality) is characterized by the reduction in the excretory and regulatory functions of the kidney. It usually occurs at the terminal stages of the disease processes. The Kidney is the primary organ responsible for the excretion of drugs and their metabolites. Risk factors for the development of nephrotoxicity for selected high-risk therapies, e.g. aminoglycosides, NSAIDs, amphotericin B, antineoplastics, ACE inhibitors, angiotensin II receptor blockers. Beside these, drug administered along with certain known nephrotoxic compounds as well as administration of drugs in hepatic disorders may also progressively influence kidney functioning. Methods that have been used to evaluate kidney function in veterinary medicine include determination of serum creatinine and BUN concentrations. Impaired renal function alters pharmacokinetics of drugs, which are mainly eliminated via kidney. Changes arising from renal impairment are decrease in renal excretion, or possibly renal metabolism. Other changes include changes in absorption, hepatic metabolism, plasma protein binding and drug distribution. The pathophysiological mechanism responsible for alterations in drug disposition, especially metabolism and renal excretion is the accumulation of uraemic toxins that may modulate cytochrome P450 enzyme activity and decrease glomerular filtration as well as tubular secretion. Dosage regimen adjustment is mainly considered in renal diseases, when the drug is mainly (at least 70% of the dose) excreted by the kidney either unchanged or as an active metabolite or the therapeutic window of the drug or the metabolite is narrow.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-pharmacokinetic-renal-failure-therapy.pdf
  • 3
  • English

REFERENCES

References: 

1. Caroline A: Renal failure-how drugs can damage the kidney. Hospital Pharmacist. 2004; 11: 48-53.
2. Jan HMF, Ingrid MB, Kampa N, Per E, Haggstrom J U and Nyman GC: Effects of caprofen on renal function during medetomidine-propofol-isoflurane anesthesia in dogs. AJVR. 2006; 67 (12):1967-1973.
3. Sandhu JS, Sehgal A, Gupta O and Singh A: Aminoglycosides nephrotoxicity
revisited. JIACM. 2007; 8(4): 331-3.
4. Kurella M: Analgesia in patients with ESRD: A review of available evidence. Am J Kidney Dis. 2003; 42(2): 217-28.
5. Curhan GC: Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;
164(14):1519-24.
6. Schoolwerth AC: Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the kidney in cardiovascular disease and the council for high blood pressure research of
the American Heart Association. Circulation. 2001; 104(16): 1985-91.
7.
Davi
d A, Long KL, Price JHA and Richard JJ: How does Angiotensin II cause renal injury. Journal of the American Heart Association. 2004; 43: 722-723.
8.
Sall
y Campoy MS, Aprn, BC and Rowland Elwell: Chronic kidney Disease.
AJN. 2005; 105(9):60-71.
9.
McName
e PT, Moore GW and McGeown MG: Gastric emptying in chronic renal failure. Br Med J. 1985;
291:310-311.
10.
DeBelli
s RJ, Smith BS, Cawley PA and Burniske GM: Drug dosing in critically ill patients with renal failure: a pharmacokinetic approach. J Intensive Care
Med. 2000; 15: 273-313.
11.
Regard
h CG: Factors contributing to variability in drug pharmacokinetics. IV. Renal excretion. J Clin Hosp Pharm. 1985;
10: 337-349.
12. Lindberg M C, Cunningham A and Lindberg NH: Acute Phenobarbital
intoxication. South Med J. 1992; 85: 803¬807.
13. Reindenberg MM: The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Am J Med. 1974; 62:466-740.
14. Mackichan JJ: Influence of protein binding and the use of unbound (free) drug concentrations. In: Evans, W.E., Schen tag, J. J. and Jusko, W. J., eds. Applied pharmacokinetics, 3rd ed. Vancouver: Applied Therapeutics, 1992; 2:1-48.
15. Prough DS: Physiologic acid-base and electrolyte changes in acute and chronic renal failure patients. Anesthesiol Clin North
America. 2000; 18(4):809-33.
16. Vree TB, Hekster YA and Anderson P G: Contribution of the human kidney to the metabolic clearance of drugs. Ann
Pharmacother 1992; 26:1421-1428.
17. Romac DR and Albertson TE: Drug interactions in the intensive care unit. Clin
Chest Med. 1999; 20: 385-399.
18. Matzke GR and Frye RF: Drug administration in patients with renal insufficiency. Minimizing renal and extra
renal toxicity. Drug Saf. 1997; 16(3): 205¬31.
19. Power BM, Millar Forbes A,
VanHeerden V and Hett K: Pharmacokinetics of drugs used in critically ill patients. Clin. Pharmacokinetic. 1998; 34:
26-48.
20. Talbert RL: Drug dosing in renal insufficiency. J clin Pharmacol. 1994;
34:99-110.
21. Lockley MR, Wise R and Dedt J: The
pharmacokinetics and tissue penetration of ofloxacin. J. Antimicrob. Chemother. 1984;
14: 647-652.
22. Gibson, TP: Renal disease and drug metabolism: An overview. Am J Kidney
Dis. 1986; 8: 7-17.
23. Lefebvre HP, Braun JP and Toutain PL : Drug prescription in renal-impaired dogs.
Rev. Med. Vet. 1996; 147: 757-782.

Thank you for copying data from http://www.arastirmax.com